Samphire Neuroscience

A headband, not a pill bottle

It is a weeknight in London, and somewhere a woman sits on the edge of her bed with a slim band across her forehead. No water glass. No blister pack. For twenty minutes a faint current works on the parts of her brain that handle mood and pain, and then she takes the band off and gets on with her evening. This is the everyday reality Samphire Neuroscience set out to manufacture: relief as a quiet habit rather than a chemical event.

The company sells one thing that matters and means to sell many more. The thing is called Nettle - a wearable that delivers transcranial direct current stimulation, or tDCS, to ease the symptoms of PMS, PMDD and menstrual pain. It is marketed as the first EU-cleared neuromodulation device built specifically for women's health, which is either a milestone or an indictment, depending on how you feel about how long that took.

Samphire is roughly twenty people, headquartered in London, and has raised about $7.77 million to argue a single point: that the brain, not the bloodstream, might be the better place to treat the monthly tax that hormones levy on tens of millions of lives.

The 190 million nobody built for

Here is the awkward number. Around 190 million people worldwide live with chronic menstrual conditions. Up to 8% of women experience PMDD, the severe end of premenstrual disorder, where mood can collapse for a predictable week each month. The overwhelming majority experience period pain at some point. And for most of that history, the menu of options ran short: take a painkiller, take a hormone, or take it.

The market that wasn't a market. For decades the numbers were enormous and the products were few - a rare case of demand politely waiting in a queue that had no front desk.

The gap was not a lack of patients. It was a lack of attention. Drugs blunt symptoms but carry side effects; hormones rewrite the whole system to fix one corner of it. Neither asks a more interesting question: what if you could change how the brain processes the signal in the first place?

A neuroscientist and a patent lawyer

In late 2021 two people decided the queue had waited long enough. Emilė Radytė, a neuroscientist trained at Harvard and Oxford whose research ran through psychiatric brain stimulation, had studied how hormonal shifts reshape mood. Alex Cook, an intellectual-property lawyer with a product streak, knew how to turn a hypothesis into something you could ship and defend. One brought the science; the other brought the scaffolding.

Their bet rested on borrowed homework. Separate labs in Australia and Brazil had each shown tDCS could help with menstrual pain and PMDD. Radytė and Cook's wager was that treating mood and pain at the same time would not just add up - it would compound. tDCS itself was no startup gamble: more than thirty years of research, they note, with no serious adverse event ever reported.

What Nettle actually does

Nettle is a headband. You wear it for twenty minutes a day, usually across the five days before your period starts. While it is on, a gentle current nudges two regions: the motor cortex, which governs how the body registers pain, and the prefrontal cortex, which governs mood. The mechanism it leans on is neuroplasticity - the brain's habit of rewiring itself - so that the luteal phase lands a little softer.

Named after a plant that stings. Nettle has a long folk history in menstrual and reproductive remedies. The irony of naming a pain device after a plant famous for causing pain was, presumably, intentional.

It is non-invasive and needs no prescription. Side effects skew mild: some itching, some tingling, the occasional brief headache that fades within half an hour. It does not, charmingly, play well with thick braided hair - a limitation the company states plainly rather than airbrushing.

The number that surprised even them

Skepticism is the right posture for a brain device sold direct to consumers, so the relevant question is whether it works. In a trial of roughly fifty participants - two-thirds of them non-white, which is worth noting in a field that often forgets to ask - the active device cut menstrual pain by an average of 52% in a single cycle. The benefit carried into the following month. Some participants even reported lighter periods afterward.

The proof is not only clinical. The first production run sold out twice before launch - a blunt market signal that people will pay around £359 for a drug-free option. The company won first place at the Healthcare Innovation World Cup. And Radytė was named a Fellow of the NHS Innovation Accelerator, opening doors to NHS partnerships and a path toward the kind of clinical integration that turns a clever device into standard care.

Sold out twice, on purpose or not. Scarcity is a marketing trick until it isn't - and a 1,000-unit first run that vanishes is usually the second kind.

Control, without the chemistry

Strip away the hardware and the mission is plain: give women more control over how hormonal change governs their lives, without asking them to medicate their whole system to do it. Samphire frames Nettle as the opening move, not the endgame - the first entry in a catalogue meant to span menstrual, hormonal and chronic pain conditions that have spent too long filed under "manage it."

That ambition is reflected in how it reaches people. Today Nettle sells direct to consumers with a 90-day guarantee. But the company is already wiring up other routes: partner clinics, employer benefits platforms, and NHS-affiliated programs - the unglamorous plumbing that decides whether a good device becomes a widely available one.

If the brain is the better lever

Return to that weeknight bedroom. The band comes off, the evening resumes, and nothing about the scene looks like medicine. That is the quiet radicalism of it. For most of history, treating the monthly tax meant either dulling the body or overruling it. Samphire's bet is that you can instead retune how the brain reads the signal - and that doing so, twenty minutes at a time, is a treatment people will actually keep up with.

The skeptic's caveats remain fair. The trials are early and small. The device is one company's read of a long research thread. tDCS is promising, not magic. But the direction is hard to argue with: a category that barely existed now has a CE-certified product, a waiting list, and an NHS pathway. If Samphire is right that the brain is the better lever, the headband on the nightstand is not the end of the story. It is the first chapter, and it stings just enough to be remembered.